Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-06-19
2007-06-19
Habte, Kahsay (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S184000
Reexamination Certificate
active
10803179
ABSTRACT:
Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.
REFERENCES:
patent: 5440013 (1995-08-01), Kahn
patent: 5475085 (1995-12-01), Kahn
patent: 5618914 (1997-04-01), Kahn
patent: 5670155 (1997-09-01), Kahn
patent: 5672681 (1997-09-01), Kahn
patent: 5693325 (1997-12-01), Kahn
patent: 5710245 (1998-01-01), Kahn
patent: 5840833 (1998-11-01), Kahn
patent: 5859184 (1999-01-01), Kahn et al.
patent: 5929237 (1999-07-01), Kahn
patent: 6013458 (2000-01-01), Kahn et al.
patent: 6020331 (2000-02-01), Kahn
patent: 6117896 (2000-09-01), Qabar et al.
patent: 6184223 (2001-02-01), Kahn et al.
patent: 6245764 (2001-06-01), Kahn et al.
patent: 6294525 (2001-09-01), Stasiak et al.
patent: 6372744 (2002-04-01), Qabar et al.
patent: 6413963 (2002-07-01), Kahn et al.
patent: 6440955 (2002-08-01), Stasiak et al.
patent: 6548500 (2003-04-01), Kahn et al.
patent: 2001/0039274 (2001-11-01), Kahn et al.
patent: 2002/0022620 (2002-02-01), Kahn et al.
patent: 2002/0065416 (2002-05-01), Stasiak et al.
patent: 2002/0068695 (2002-06-01), Scolastico et al.
patent: 2003/0021773 (2003-01-01), Moroder et al.
patent: 2003/0027819 (2003-02-01), Qabar et al.
patent: 2003/0105103 (2003-06-01), Golebiowski et al.
patent: 2004/0072831 (2004-04-01), Moon et al.
patent: WO 94/03494 (1994-02-01), None
patent: WO 97/15577 (1997-05-01), None
patent: WO 98/49168 (1998-11-01), None
patent: WO 01/00210 (2001-01-01), None
patent: WO 01/16135 (2001-03-01), None
patent: WO 03/006447 (2003-01-01), None
patent: WO 03/031448 (2003-04-01), None
Arango, D. et al., “c-myc/p53 Interaction Determines Sensitivity of Human Colon Carcinoma Cells to 5-Fluorouraciein Vitroandin Vivo,” Cancer Research 61: 4910-4915, Jun. 15, 2001.
Batlle, E. et al., “β-Catenin and TCF Mediate Cell Positioning in the Intestinal Epithelium by Controlling the Expression of EphB/EphrinB,”Cell, 111:251-253, Oct. 18, 2002.
Behrens, J. et al., “Functional interaction of β-catenin with the transcription factor LEF-1,”Nature 382: 638-642, Aug. 15, 1996.
Bienz and Clevers, “Linking Colorectal Cancer to Wnt Signaling,”Cell, 103:311-320, Oct. 13, 2000.
Blanc-Brude, O. P. et al., “Inhibitor of apoptosis protein surviving regulates vascular injury,”Nature Medicine, 8(9):987-994, Sep. 2002.
Caca, K. et al., “β- and γ-Catenin Mutations, but not E-Cadherin Inactivation, Underlie T-Cell Factor/Lymphoid Enhancer Factor Transcriptional Deregulation in Gastric and Pancreatic Cancer,”Cell Growth&Differentiation 10: 369-376, 1999.
Cadigan and Nusse, “Wnt signaling: a common theme in animal development,”Genes&Development 11: 3286-3305, 1997.
Cheguillaume, A. et al., “New Potential Monomers for Solid Phase Synthesis of Hydrazinopeptoids: theNα-Substituted-N62-Protected Hydrazinoglycines and Hydrazonoglycinals,”Synlett2000, No. 3, pp. 331-334, Mar. 2000.
Chen, S. et al., “Wnt-1 Signaling Inhibits Apoptosis by Activating β-Catenin/T Cell Factor-mediated Transcription,”The Journal of Cell Biology 152(1): 87-96, Jan. 8, 2001.
Chenn and Walsh, “Regulation of Cerebral Cortical Size by Control of Cell Cycle Exit in Neural Precursors,”Science, 297:365-369, Jul. 19, 2002.
Chrivia, J.C. et al., “Phosphorylated CREB binds specifically to the nuclear protein CBP,”Nature 365: 855-859, Oct. 28, 1993.
Crawford, H.C. et al., “The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors,”Oncogene, 18: 2883-2891, 1999.
Daniels, D. L. et al., “β-catenin: molecular plasticity and drug design,”TRENDS in Biochemical Sciences, 26(11):672-678, Nov. 11, 2001.
DasGupta and Fuchs, “Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation,”Development, 126: 4557-4568, 1999.
De Farrari and Inestrosa, “Wnt signaling function in Alzheimer's disease,”Brain Research Reviews, 33: 1-12, 2000.
Dolle, R.E. “Comprehensive Survey of Combinatorial Library Synthesis: 1999,”Journal of Combinatorial Chemistry, 2(5): 383-433, Sep./Oct. 2000.
Dooley and Houghten, “The use of positional scanning synthetic peptide combinatorial libraries for the rapid determination of opioid receptor ligands,”Life Sciences, 52(18): 1509-1517, 1993.
Dooley, C.T. et al., “Acetalins: Opioid receptor antagonists determined through the use of synthetic peptide combinatorial libraries,”Proc. Natl. Acad. Sci. USA, 90: 10811-10815, Nov. 1993.
Dooley, C.T. et al., “An All D-Amino Acid Opioid Peptide with Central Analgesic Activity from a Combinatorial Library,”Science 266: 2019-2022, Dec. 23, 1994.
Eckner, R. et al., “Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor,”Genes&Development, 8: 869-884, 1994.
Eichler, J. et al., “Cyclic Peptide Template Combinatorial Libraries: Synthesis and Identification of Chymotrypsin Inhibitors,”Peptide Research, 7(6):300-307, 1994.
Fraser, P.E. et al., “Presenilin function: connections to Alzheimer's disease and signal transduction,”Biochem. Soc. Symp., 67:89-100, 2001.
Fuchs, E., “Beauty is Skin Deep: The Fascinating Biology of the Epidermis and its Appendages,”The Harvey Lectures, Delivered Under the Auspices of The Harvey Society of New York, 1998-1999, Wiley-Liss, A John Wiley & Sons, Inc., Publication, Series 94, 47-48, 2000.
Fujimuro, M. et al., “A novel viral mechanism for dysregulation of β-catenin in Kaposi's sarcoma-associated herpesvirus latency,”Nature Medicine, 9(3):300-306, Mar. 2003.
Gallop, M.A. et al., “Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries,”Journal of Medicinal Chemistry, 37(9):1233-1251, Apr. 29, 1994.
Gat, U. et al., “De Novo Hair Follicle Morphogenesis and Hair Tumors in Mice Expressing a Truncated β-Catenin in Skin,”Cell, 95:605-614, Nov. 25, 1998.
Gomez, M. R., “History of the tuberous sclerosis complex,”Brain&Development, 17(suppl):55-7, 1995.
Graminski and Lerner, “A Rapid Bioassay for Platelet-Derived Growth Factor β-Receptor Tyrosine Kinase Function,”Bio/Technology 12: 1008-1011, Oct. 12, 1994.
Grossman, D. et al., “Inhibition of melanoma tumor growthin vivoby surviving targeting,”PNAS, 98(2):635-640, Jan. 16, 2001.
Hanai, J., et al., “Endostatin is a potential inhibitor of Wnt signaling,”The Journal of Cell Biology, 158(3):529-539, Aug. 5, 2002.
Hartmann, D., “From Alzheimer's disease to skin tumors: The catenin connection,”Proc. Natl. Acad. Sci. USA, 98(19): 10522-10523, Sep. 11, 2001.
Hayashi, S. et al., “ADrosophilahomolog of the tumor suppressor gene adenomatous polyposis coli down-regulates β-catenin but its zygotic expression is not essential for the regulation of Armadillo,”Proc. Natl. Acad. Sci. USA, 94:242-247, Jan. 1997.
He, Tong-Chuan et al., “Identification of c-MYCas a
Chung Jae Uk
Eguchi Masakatsu
Jeong Kwang Won
Kahn Michael
Lee Sung Chan
Choongwae Pharma Corporation
Habte Kahsay
Seed IP Law Group PLLC
LandOfFree
Reverse-turn mimetics and method relating thereto does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reverse-turn mimetics and method relating thereto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reverse-turn mimetics and method relating thereto will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3863195